Table 3.
Clinical trials in HCV vaccine. All data below obtained from www.clinicaltrials.gov.
| Study Type | Vaccine biology | Study Number | Individual type | Outcome |
|---|---|---|---|---|
| Preventative | AdCh3NSmut1 MVA-NSmut | NCT01436357 | Healthy at risk population | Pending/Jan 2016 |
| Preventative | AdCh3NSmut1 MVA-NSmut | NCT02362217 | Healthy subjects/HIV + | Pending/Oct 2016 |
| Therapeutic/peptide antigens | PEV2A PEV2B | NCT00445419 | Hep C+ | Updated 2/2010 – no results |
| Therapeutic | MRKAd5 HIV-1 gag vaccine | NCT00857311 | Hep C+ | Canceled - non-efficacious results of previous study using similar agent |
| Therapeutic | Recombinant IMPs Ad6NSmut and MVA-NSmu | NCT01701336 | Chronic Hep C+ | Last updated 2013, no results |
| Therapeutic | TG4040 | NCT00449124 | Chronic Hep C+ | Withdrawn |
| Therapeutic | GI-5005 | NCT00124215 | Chronic Hep C+ | Completed 2010 – no results |
| Therapeutic | IC41 | NCT00601770 | Chronic Hep C+ | Phase 2 – no results 2014 |
| Therapeutic – Genotype 1a | Autologous dendritic cells transduced with Ad encoding NS3 | NCT02309086 | Chronic Hep C+ | Study complete 2015 – no results reported |